All Stories

IconOVir, 4 years on from flashy launch, sells oncolytic virus to UroGen for $4M in stock

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette-Guérin (BCG) therapy.

Feb 20, 2025 - 15:33
 0
IconOVir, 4 years on from flashy launch, sells oncolytic virus to UroGen for $4M in stock
UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette-Guérin (BCG) therapy.
Read More

Tags:

Previous Article

Alibaba to ‘aggressively’ invest in AI over next three years

Next Article

Risky weight loss, grad school acceptance cuts, and more major biotech news of t...

Related Posts

Acelyrin to be absorbed into Alumis in all-stock merger

Acelyrin to be absorbed into Alumis in all-stock merger

Feb 9, 2025  0

Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger

Kineta sells Genentech and Merck deals to investor ahea...

Feb 10, 2025  0

Cabaletta’s CAR-T shows ‘robust benefit’ in lupus patients, teeing up registrational trial plans

Cabaletta’s CAR-T shows ‘robust benefit’ in lupus patie...

Feb 19, 2025  0